As it is said in a current communication, the coronavirus and COVID-19 are currently the subject of intensive research at the Ulm University Hospital.
The corona pandemic is working on strategies to curb the spread of the virus worldwide.
Above all, medication is needed quickly, which can be used in particular for difficult courses.
A drug against bone marrow diseases could possibly help.
Do me a favor: Please SHARE this post.
According to experts, vaccines against the new coronavirus SARS-CoV-2 are unlikely to be available this year.
Therefore, the hopes are that faster it will be possible to find drugs to treat those already infected.
Here, funds are also used that have already been approved.
The effect of a preparation against diseases of the bone marrow for the treatment of COVID-19 is now being investigated in a study.
COVID-19: treatment with medication for diseases of the bone marrow
The experts at the Clinic for Internal Medicine III are now taking part in a clinical study for the treatment of corona patients suffering from more severe symptoms.
Those affected receive the drug ruxolitinib, which has been used to treat myeloid bone marrow diseases.
Six further German clinics are expected to participate in the study; a total of 200 COVID-19 patients are to be enrolled.
Treatment of patients with severe symptoms
According to the release, it is being investigated whether the drug can stop the severe inflammatory reaction of the lungs and other organs that is common in COVID-19.
The cause of the deterioration in lung function that occurs in many patients is, among other things, a strong inflammatory reaction in the lungs, which is triggered by the novel virus and can cause severe shortness of breath.
Although the course of the disease in COVID-19 is very different and unspecific, according to the experts, around 15 percent of the patients are treated in a clinic and require oxygen therapy.
Up to five percent of those affected must therefore be cared for in an intensive care unit.
As explained in the communication, the drug ruxolitinib inhibits the so-called Janus kinases, i.e. enzymes that play an important role in inflammatory reactions of various diseases.
Because people with severe corona suffer primarily from violent and sometimes life-threatening respiratory complications, the inhibition of this inflammatory reaction is an important part of the therapy of COVID-19.
“The drug can effectively suppress released messengers of the inflammatory reaction.
Our goal is to stop the inflammatory reaction with early administration of ruxolitinib, in order to prevent artificial ventilation in the intensive care unit for our patients.
“
“The excessive inflammatory reaction that occurs in corona disease primarily in the lungs but also in other organs is the background for the use of ruxolitinib,” explains senior physician Professor Konstanze Döhner, who heads the study at the Ulm University Hospital.
Research is now underway to determine whether the preparation can also be used to treat COVID-19.
Covid-19 patients who are treated in hospital at the Ulm University Hospital or other participating clinics can participate.
Tekk.tv health
–
